Auxilium Pharmaceuticals Inc. (AUXL) announced that it has received marketing approval from the U.S. Food and Drug Administration for XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord. The Company expects to begin shipping XIAFLEX to its distribution partners in early March in advance of a launch planned for late March.
The company said that XIAFLEX can cause serious side effects, including Tendon or ligament damage, Nerve injury or other serious injury of the hand, Allergic Reactions.
For comments and feedback: editorial@rttnews.com